NYSE$ABBV
AbbVie Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
AbbVie reported Q4 2025 revenue of $16.6B and adjusted diluted EPS of $2.71.
Fourth-quarter net revenues grew 10% to $16.6 billion. GAAP diluted EPS was $1.02; adjusted diluted EPS was $2.71 after IPR&D charges. Immunology sales led by Skyrizi and Rinvoq; 2026 adjusted EPS guidance is $14.37–14.57.
- Q4 revenue $16.6B (+10% reported).
- Skyrizi $5.0B (+32.5%); Rinvoq $2.4B (+29.5%).
- Adjusted Q4 EPS $2.71.
- 2026 adjusted EPS guide $14.37–$14.57.
Headline financials
Revenue & EPS history
AbbVie · Revenue · Quarterly
$16.6B
Revenue by segment
AbbVie · $13.1B total across 6 segments · Q3 2023
- Immunology$6.78B-11.3%51.6%
- Neuroscience$2.04B—15.5%
- Oncology$1.51B-8.4%11.5%
- Aesthetics$1.24B—9.4%
- Other Key Products$963M—7.3%
- Eye Care$605M—4.6%
Forward guidance
2026 adjusted diluted EPS guidance of $14.37–14.57, excluding acquired IPR&D and milestones.
Tailwinds
- Skyrizi and Rinvoq immunology growth remain core drivers.
- Neuroscience portfolio grew high teens in Q4.
- Full-year revenue exceeded $61 billion (+8.6%).
Headwinds
- Humira erosion continues.
- Aesthetics revenue declined on softer demand.
- Large IPR&D charges weighed on reported EPS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+0.9%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+3.7%
Avg return
30 days after
55%
32 / 58 earnings
Positive
+17.2%
Q3 2015
Best reaction
-10.2%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +5.3% | +10.3% | |
| Q4 2025 | -7.1% | -1.1% | +2.0% | |
| Q3 2025 | -7.1% | -5.0% | -0.2% | |
| Q2 2025 | +1.0% | +1.4% | +8.5% | |
| Q1 2025 | +3.2% | +8.2% | +1.6% | |
| Q4 2024 | +4.7% | +9.2% | +19.0% | |
| Q3 2024 | +7.6% | +5.8% | -3.4% | |
| Q2 2024 | +5.1% | +6.0% | +12.1% | |
| Q1 2024 | -3.4% | -3.3% | -6.1% | |
| Q4 2023 | +2.2% | +4.4% | +6.8% | |
| Q3 2023 | -2.3% | -1.9% | -4.5% | |
| Q2 2023 | +6.3% | +4.7% | +3.4% | |
| Q1 2023 | -6.6% | -6.3% | -15.0% | |
| Q4 2022 | +5.1% | +5.5% | +3.5% | |
| Q3 2022 | -4.6% | -5.9% | +4.0% | |
| Q2 2022 | -6.4% | -5.7% | -8.9% | |
| Q1 2022 | -5.4% | -3.0% | -4.0% | |
| Q4 2021 | +2.7% | +4.0% | +9.9% | |
| Q3 2021 | +4.7% | +7.2% | +6.2% | |
| Q2 2021 | -2.9% | -3.2% | +0.6% | |
| Q1 2021 | +3.4% | +4.4% | +2.1% | |
| Q4 2020 | +4.9% | +3.3% | +3.1% | |
| Q3 2020 | +9.4% | +17.1% | +30.0% | |
| Q2 2020 | -0.1% | -2.9% | -1.9% | |
| Q1 2020 | -0.4% | +3.9% | +12.7% | |
| Q4 2019 | +8.7% | +12.2% | +1.9% | |
| Q3 2019 | +4.3% | +3.2% | +10.3% | |
| Q2 2019 | +0.8% | -0.1% | -1.0% | |
| Q1 2019 | +1.3% | +0.9% | +1.8% | |
| Q4 2018 | -10.2% | -7.9% | -6.8% | |
| Q3 2018 | +3.0% | +8.4% | +17.5% | |
| Q2 2018 | -2.7% | -0.0% | +3.7% | |
| Q1 2018 | +7.5% | +11.1% | +10.0% | |
| Q4 2017 | +12.9% | +3.6% | +9.6% | |
| Q3 2017 | +1.6% | +3.2% | +5.8% | |
| Q2 2017 | -2.5% | -1.4% | +1.0% | |
| Q1 2017 | +1.4% | +2.4% | +1.6% | |
| Q4 2016 | -1.4% | -0.6% | +1.3% | |
| Q3 2016 | -9.2% | -7.6% | -1.5% | |
| Q2 2016 | +3.4% | +2.9% | -0.2% | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | -2.6% | — | — | |
| Q3 2015 | +17.2% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -3.8% | — | — | |
| Q3 2014 | +3.4% | — | — | |
| Q2 2014 | -0.6% | — | — | |
| Q1 2014 | +3.1% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q4 2013 | -2.0% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2012 | -0.0% | — | — | |
| Q2 2013 | +1.9% | — | — | |
| Q4 2012 | -1.5% | — | — | |
| Q1 2012 | -1.5% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro